22:03 , Dec 1, 2017 |  BC Week In Review  |  Company News

Codexis, Nestle deal

In October, the Nestle Health Science subsidiary of Nestle S.A. (SIX:NESN) obtained an option from Codexis Inc. (NASDAQ:CDXS) to license exclusive worldwide rights to CDX-6114, an oral enzyme, to treat phenylketonuria. Codexis received $14 million up...